A Partnership on the Rocks? Drug Makers and their CMOs
This article was originally published in The Gold Sheet
Drug makers want to have more strategic relationships with their contract providers and are increasingly viewing partnerships as a business necessity. Yet ineffective communication and inflexible pricing schemes may be undermining these relationships.
You may also be interested in...
Proposal could yield a bounty of new options for innovative drug delivery systems.
Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.
FDA’s draft guidance on transdermal and topical delivery systems says manufacturers can leverage pharmaceutical development studies principles for device design control requirements.